UPDATE ON PFIZER’S PHASE 1B OPEN-LABEL MINI-DYSTROPHIN GENE THERAPY TRIAL FOR DUCHENNE, page-76

Messy.

With readout due mid year why would Sarepta exit the deal?

Probs because there is a milestone payment due as soon as results drop...and results crap.

Back to DMD and LGMD for Sarepta.

Unfortunately they have put all their eggs in the Gene Therapy basket....

...at a time when the new game in town is mRNA tech.

Pfizer this week announced more investment / partnerships in the mRNA space (Codex & Acuitas).

"We truly believe that the mRNA technology is very powerful. It's not the holy grail, but it is very powerful," Bourla said.

.